Wire flash
Virax Biolabs signs exclusive immune profiling supply deal with Fosun Diagnostics for six Southeast Asian countries
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Virax Biolabs Group, through its UK subsidiary, has signed an exclusive commercial supply agreement with Fosun Diagnostics to provide its ImmuneSelect immune profiling product line across six Southeast Asian countries: Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. The deal covers research-use-only ELISpot assay plates that measure cellular immune responses, with initial focus on tuberculosis-related research in Thailand, where Fosun has identified immediate customer interest. The agreement includes structured, volume-based pricing tiers and allows for immediate product supply upon purchase orders. It provides a framework for phased expansion, potentially including additional products, larger-scale supply, and OEM or private-label arrangements. The exclusivity is tied to minimum purchase and performance criteria. Virax Biolabs CEO James Foster called it a major step for commercial rollout in Southeast Asia, while Fosun MedTech's Leon Zhang expressed interest in evaluating the ELISpot platform across regional markets.
Source report
Source: Medical Device Network Author: Salong Debbarma
Virax Biolabs Group subsidiary Virax Biolabs (UK) has signed an exclusive commercial supply agreement with Fosun Diagnostics for its research-use-only ImmuneSelect immune profiling product line.
Fosun is the key entity of the diagnostics business under Fosun Medtech, a division of Fosun Pharma.
Geographic Scope
The agreement covers six Southeast Asian countries:
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
Key Terms and Commercial Structure
The agreement allows for immediate product supply in response to purchase orders and aims to support near-term revenue prospects and regional business growth.
Under the agreement, Virax Biolabs will provide ImmuneSelect products—including ELISpot assay plates used to measure cellular immune responses—to Fosun Diagnostics based on structured, volume-based pricing tiers.
The exclusivity of the agreement is tied to minimum purchase and performance criteria.
Initial Focus and Expansion Plans
The collaboration initially focuses on tuberculosis-related research applications in Thailand, where Fosun has identified immediate customer interest and begun evaluation activities through Fosun Pharma's regional network. This rollout could later extend across other countries in the region.
The deal provides a framework for phased expansion that may include:
- Additional products
- Larger-scale supply
- Potential original equipment manufacturer (OEM) or private-label arrangements
Executive Commentary
James Foster, Chairman and CEO of Virax Biolabs, said:
"This agreement represents a major step forward in the commercial rollout of our ImmuneSelect platform across Southeast Asia. It establishes a structured multi-country framework with one of Asia's leading diagnostics groups, enabling immediate commercial activity and a clear pathway for scalable regional expansion."
Leon Zhang, Head of International Commercial Business for Fosun MedTech China Domestic Business, said:
"We are pleased to collaborate with Virax Biolabs as we evaluate ELISpot-based research applications across Southeast Asia. Virax's ImmuneSelect ELISpot platform provides a strong option for our evaluation activities, and we look forward to assessing its performance across multiple regional markets."
Note
ImmuneSelect is distinct from ViraxImmune, Virax's separate diagnostic platform that remains under development.
"Virax Biolabs enters immune profiling product supply deal with Fosun" was originally created and published by Medical Device Network, a GlobalData owned brand.
Source
Yahoo FinanceWestern
Part of this Story
Virax Biolabs Shares Surge on Exclusive Fosun Distribution Deal for Southeast Asia